Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible
OBJECTIVES: To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) have similar benefits and drug survival as tho...
Published in: | RMD Open |
---|---|
Main Authors: | , , , , , , |
Format: | Text |
Language: | English |
Published: |
BMJ Publishing Group
2019
|
Subjects: | |
Online Access: | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667974/ https://doi.org/10.1136/rmdopen-2019-000984 |
id |
ftpubmed:oai:pubmedcentral.nih.gov:6667974 |
---|---|
record_format |
openpolar |
spelling |
ftpubmed:oai:pubmedcentral.nih.gov:6667974 2023-05-15T16:52:33+02:00 Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn 2019-07-16 http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667974/ https://doi.org/10.1136/rmdopen-2019-000984 en eng BMJ Publishing Group http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667974/ http://dx.doi.org/10.1136/rmdopen-2019-000984 © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. CC-BY-NC Psoriatic Arthritis Text 2019 ftpubmed https://doi.org/10.1136/rmdopen-2019-000984 2019-08-18T00:29:09Z OBJECTIVES: To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) have similar benefits and drug survival as those patients who would have (incl). METHODS: All patients with rheumatic disorders who are treated with biological disease-modifying antirheumatic drugs in Iceland are registered in ICEBIO. On 1 February 2016, 329 individuals with PsA were registered in ICEBIO, of whom 231 had data available for their first start of TNFi and could be evaluated according to the inclusion criteria of the respective RCTs. Disease activity was collected at baseline using Visual Analogue Scale (pain, fatigue and global (patient and physician) assessments), swollen joint count (SJC) and tender joint count (TJC), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) and Health Assessment Questionnaire (HAQ). Treatment response was measured at 6 and 18 months according to American College of Rheumatology response criteria, DAS28-CRP and Disease Activity Score in Psoriatic Arthritis for 28 joints. Drug survival rate was also analysed. RESULTS: The demographics of these two groups were similar at baseline, although the incl group had higher SJC (5.5 vs 3.8) and subsequently higher DAS28-CRP (4.6 vs 4.2). While a larger change in disease activity was observed in the incl group with respect to HAQ and SJC, both groups had similar disease activity at follow-up. Drug survival was similar in both groups. CONCLUSIONS: Patients with PsA who would not have fulfilled the inclusion criteria in RCTs reach similar disease activity scores at follow-up of 6 and 18 months and have similar drug survival as those patients who would have been included in RCTs. Text Iceland PubMed Central (PMC) RMD Open 5 2 e000984 |
institution |
Open Polar |
collection |
PubMed Central (PMC) |
op_collection_id |
ftpubmed |
language |
English |
topic |
Psoriatic Arthritis |
spellingShingle |
Psoriatic Arthritis Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible |
topic_facet |
Psoriatic Arthritis |
description |
OBJECTIVES: To determine in a retrospective cohort whether patients with psoriatic arthritis (PsA) who would not have fulfilled the inclusion criteria for randomised controlled trials (RCTs) for the TNF inhibitor (TNFi) chosen for their treatment (excl) have similar benefits and drug survival as those patients who would have (incl). METHODS: All patients with rheumatic disorders who are treated with biological disease-modifying antirheumatic drugs in Iceland are registered in ICEBIO. On 1 February 2016, 329 individuals with PsA were registered in ICEBIO, of whom 231 had data available for their first start of TNFi and could be evaluated according to the inclusion criteria of the respective RCTs. Disease activity was collected at baseline using Visual Analogue Scale (pain, fatigue and global (patient and physician) assessments), swollen joint count (SJC) and tender joint count (TJC), Disease Activity Score 28-joint count C reactive protein (DAS28-CRP) and Health Assessment Questionnaire (HAQ). Treatment response was measured at 6 and 18 months according to American College of Rheumatology response criteria, DAS28-CRP and Disease Activity Score in Psoriatic Arthritis for 28 joints. Drug survival rate was also analysed. RESULTS: The demographics of these two groups were similar at baseline, although the incl group had higher SJC (5.5 vs 3.8) and subsequently higher DAS28-CRP (4.6 vs 4.2). While a larger change in disease activity was observed in the incl group with respect to HAQ and SJC, both groups had similar disease activity at follow-up. Drug survival was similar in both groups. CONCLUSIONS: Patients with PsA who would not have fulfilled the inclusion criteria in RCTs reach similar disease activity scores at follow-up of 6 and 18 months and have similar drug survival as those patients who would have been included in RCTs. |
format |
Text |
author |
Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn |
author_facet |
Palsson, Olafur Love, Thorvardur Jon Gunnarsdottir, Anna Ingibjorg Gunnarsson, Petur Sigurdur Runarsdottir, Eydis Erla Krogh, Niels Steen Gudbjornsson, Bjorn |
author_sort |
Palsson, Olafur |
title |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible |
title_short |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible |
title_full |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible |
title_fullStr |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible |
title_full_unstemmed |
Patients with psoriatic arthritis who are not eligible for randomised controlled trials for TNF inhibitors have treatment response and drug survival similar to those who are eligible |
title_sort |
patients with psoriatic arthritis who are not eligible for randomised controlled trials for tnf inhibitors have treatment response and drug survival similar to those who are eligible |
publisher |
BMJ Publishing Group |
publishDate |
2019 |
url |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667974/ https://doi.org/10.1136/rmdopen-2019-000984 |
genre |
Iceland |
genre_facet |
Iceland |
op_relation |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6667974/ http://dx.doi.org/10.1136/rmdopen-2019-000984 |
op_rights |
© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
op_rightsnorm |
CC-BY-NC |
op_doi |
https://doi.org/10.1136/rmdopen-2019-000984 |
container_title |
RMD Open |
container_volume |
5 |
container_issue |
2 |
container_start_page |
e000984 |
_version_ |
1766042891379015680 |